Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00259753 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of Small Interfering Ribonucleic Acid (RNA) Molecule (Cand5) to Treat Wet Age-Related Macular Degeneration
A Phase 2 study, sponsored by OPKO Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
NCT00259753 is a Phase 2 study that has completed, run by OPKO Health. The registered enrollment target is 120 participants.
The verdict
NCT00259753, a Phase 2 study, has completed, sponsored by OPKO Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the safety and preliminary efficacy of three doses of Cand5. Cand5, a small interfering RNA molecule that selectively silences the mRNA encoding for VEGF.
Interventions
- DRUG Bevasiranib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2005-07 |
| Est. Completion | 2007-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00259753
The ClinicalTrials.gov registry entry for NCT00259753 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OPKO Health, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bevasiranib is the first listed.
NCT00259753 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00259753 about?
NCT00259753 is a clinical study titled "Safety and Efficacy Study of Small Interfering Ribonucleic Acid (RNA) Molecule (Cand5) to Treat Wet Age-Related Macular Degeneration". The objective of this study is to evaluate the safety and preliminary efficacy of three doses of Cand5. Cand5, a small interfering RNA molecule that selectively silences the mRNA encoding for VEGF.
What is the current status of trial NCT00259753?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2005-07. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00259753?
The interventions under investigation include: Bevasiranib (DRUG).
Who is sponsoring clinical trial NCT00259753?
This trial is sponsored by OPKO Health, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.